Skip to main
DGX

Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics (DGX) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 27%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

Quest Diagnostics is strategically positioned in the healthcare industry through its national network of patient service centers and partnerships, as well as its advanced diagnostic solutions segment. Fiscal year 2026 guidance being moved higher, strong core demand trends, and potential for share gains and M&A growth contribute to a positive outlook, despite a premium stock valuation and potential headwinds such as weather impacts and cost investment for Project Nova. Overall, this company has solid financials and maintains a strong position in the market, suggesting a positive outlook for the future.

Bears say

Quest Diagnostics is facing challenges in its core clinical testing business due to growing competition and pricing pressures. While the company is seeing strong growth in advanced diagnostic areas like Alzheimer's testing, it is not enough to offset the declining revenue in its traditional testing segments. Additionally, Quest's attempts to cut costs and improve margins through the use of AI may not be enough to sustain long-term growth and profitability in an increasingly competitive market.

Quest Diagnostics (DGX) has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 27% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quest Diagnostics (DGX) Forecast

Analysts have given Quest Diagnostics (DGX) a Hold based on their latest research and market trends.

According to 11 analysts, Quest Diagnostics (DGX) has a Hold consensus rating as of Jun 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $215.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $215.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quest Diagnostics (DGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.